Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Infection ; 52(3): 1099-1111, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38366304

ABSTRACT

PURPOSE: In late 2022, a surge of severe S. pyogenes infections was reported in several European countries. This study assessed hospitalizations and disease severity of community-acquired bacterial infections with S. pyogenes, S. pneumoniae, N. meningitidis, and H. influenzae among children in North Rhine-Westphalia (NRW), Germany, during the last quarter of 2022 compared to long-term incidences. METHODS: Hospital cases due to bacterial infections between October and December 2022 were collected in a multicenter study (MC) from 59/62 (95%) children's hospitals in NRW and combined with surveillance data (2016-2023) from the national reference laboratories for streptococci, N. meningitidis, and H. influenzae. Overall and pathogen-specific incidence rates (IR) from January 2016 to March 2023 were estimated via capture-recapture analyses. Expected annual deaths from the studied pathogens were calculated from national death cause statistics. RESULTS: In the MC study, 153 cases with high overall disease severity were reported with pneumonia being most common (59%, n = 91). IRs of bacterial infections declined at the beginning of the COVID-19 pandemic and massively surged to unprecedented levels in late 2022 and early 2023 (overall hospitalizations 3.5-fold), with S. pyogenes and S. pneumoniae as main drivers (18-fold and threefold). Observed deaths during the study period exceeded the expected number for the entire year in NRW by far (7 vs. 0.9). DISCUSSION: The unprecedented peak of bacterial infections and deaths in late 2022 and early 2023 was caused mainly by S. pyogenes and S. pneumoniae. Improved precautionary measures are needed to attenuate future outbreaks.


Subject(s)
Community-Acquired Infections , Disease Outbreaks , Humans , Germany/epidemiology , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Child , Child, Preschool , Infant , Disease Outbreaks/statistics & numerical data , Adolescent , Female , Male , Hospitalization/statistics & numerical data , Bacterial Infections/epidemiology , Incidence , Infant, Newborn , Streptococcus pyogenes
2.
Front Immunol ; 12: 617925, 2021.
Article in English | MEDLINE | ID: mdl-34149682

ABSTRACT

Group B Streptococcus (GBS) is a common intestinal colonizer during the neonatal period, but also may cause late-onset sepsis or meningitis in up to 0.5% of otherwise healthy colonized infants after day 3 of life. Transmission routes and risk factors of this late-onset form of invasive GBS disease (iGBS) are not fully understood. Cases of iGBS with recurrence (n=25) and those occurring in parallel in twins/triplets (n=32) from the UK and Ireland (national surveillance study 2014/15) and from Germany and Switzerland (retrospective case collection) were analyzed to unravel shared (in affected multiples) or fixed (in recurrent disease) risk factors for GBS disease. The risk of iGBS among infants from multiple births was high (17%), if one infant had already developed GBS disease. The interval of onset of iGBS between siblings was 4.5 days and in recurrent cases 12.5 days. Disturbances of the individual microbiome, including persistence of infectious foci are suggested e.g. by high usage of perinatal antibiotics in mothers of affected multiples, and by the association of an increased risk of recurrence with a short term of antibiotics [aOR 4.2 (1.3-14.2), P=0.02]. Identical GBS serotypes in both recurrent infections and concurrently infected multiples might indicate a failed microbiome integration of GBS strains that are generally regarded as commensals in healthy infants. The dynamics of recurrent GBS infections or concurrent infections in multiples suggest individual patterns of exposure and fluctuations in host immunity, causing failure of natural niche occupation.


Subject(s)
Anti-Bacterial Agents/adverse effects , Drug-Related Side Effects and Adverse Reactions/epidemiology , Dysbiosis/epidemiology , Sepsis/epidemiology , Streptococcal Infections/epidemiology , Streptococcus/physiology , Age of Onset , Anti-Bacterial Agents/therapeutic use , Dysbiosis/etiology , Europe/epidemiology , Female , Humans , Infant, Newborn , Male , Microbiota , Pregnancy , Pregnancy Complications, Infectious , Recurrence , Retrospective Studies , Risk Factors , Triplets , Twins
3.
Case Rep Pediatr ; 2019: 7381597, 2019.
Article in English | MEDLINE | ID: mdl-30800484

ABSTRACT

We present a case of a nearly 3-year-old girl who was admitted to hospital due to severe hypernatremia (196 mmol/l). Her medical history included central hypothyreosis and growth hormone deficiency. Rehydration and normalization of sodium was achieved according to guidelines. On the fourth day of hospitalization, the patient developed tremor, ataxia, and rigor. Cranial magnetic resonance imaging (cMRI) was performed and (mis)interpreted for meningoencephalitis, with corresponding diagnostic and therapeutic implications. The patient had extrapontine myelinolysis. The child recovered completely after hospitalization for nearly 2 weeks.

4.
J Pediatr Endocrinol Metab ; 30(10): 1121-1124, 2017 Oct 26.
Article in English | MEDLINE | ID: mdl-28820737

ABSTRACT

A 9-month-old Turkish girl was admitted several times within 3 months to the hospital in reduced general condition and with extreme tachypnea. The patient had been diagnosed with phenylketonuria (PKU) in newborn screening and has been treated with a low phenylalanine diet and amino acid supplements. Each time an unexplained pronounced metabolic acidosis was noted, and the child was treated with sodium-bicarbonate and glucose-electrolyte infusions. The acidosis with only slightly abnormal glucose, normal lactate levels and pronounced ketonuria suggested a defect in ketone body utilization. Succinyl-CoA: 3-oxoacid CoA transferase (SCOT) enzyme activity was low in patient's fibroblasts. Mutation analysis of the corresponding OXCT1 gene revealed that the patient was a homozygous carrier of the mutation c.1523T>C (p.V508A). We conclude that SCOT deficiency should be considered in the differential diagnosis in patients with recurrent metabolic acidotic episodes, even if they are already known to have a metabolic disease unrelated to this.


Subject(s)
Acidosis/complications , Coenzyme A-Transferases/deficiency , Phenylketonurias/complications , Acidosis/drug therapy , Acidosis/genetics , Coenzyme A-Transferases/genetics , DNA Mutational Analysis , Female , Glucose/therapeutic use , Humans , Infant , Mutation , Sodium Bicarbonate/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...